
Bristol Myers Squibb (NYSE: BMY)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Bristol Myers Squibb Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Bristol Myers Squibb Company Info
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
News & Analysis
Why Bristol Myers Squibb Stock Is Fading Today
A high-profile clinical failure by a rival is weighing on the drugmaker's shares today.
Could Bristol-Myers Squibb Stock Help You Retire A Millionaire?
It isn't exactly a growth stock, but it has a few features that could make you richer.
What Is the Fortune 100?
Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid Investment
The stock isn't nearly as risky as its low valuation suggests.
Investing in Cancer Stocks
Learn about some of the leading cancer stocks in the U.S stock market this year.
3 Things About Bristol Myers Squibb That Smart Investors Know
The stock is down this year, but will its struggles fade into the rearview mirror?
Could Bristol Myers Squibb Stock Help You Become a Millionaire?
Bristol Myers has been investing in growth, but will it be enough to get investors bullish on its struggling stock?
2 High-Yield Dividend Stocks to Buy Now
These two blue-chip stocks sport generous yields.
Valuation
Podcast Episodes

The Top Biotech Stocks to Watch Following ASH 2019
The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.

3 Biggest Stories at the J.P. Morgan Healthcare Conference This Year
These stocks skyrocketed following exciting announcements.
Carl Icahn Takes Aim at Bristol-Myers Squibb
Carl Icahn's reportedly focusing his brand of investor activism on Bristol-Myers Squibb, but it's anyone's guess if he'll be able to convince the company to sell. Also, Celgene delivers a phase 3 win with blockbuster implications.
Heart-Thumping, Game-Changing Ways We're Treating Cardiovascular Disease
In this Valentine's Day edition, Industry Focus explores cholesterol busters, heart surgery, and the latest in anticoagulants.
Earnings Transcripts
Bristol Myers Squibb (BMY) Q3 2023 Earnings Call Transcript
BMY earnings call for the period ending September 30, 2023.
Bristol Myers Squibb (BMY) Q2 2023 Earnings Call Transcript
BMY earnings call for the period ending June 30, 2023.
Bristol-Myers Squibb (BMY) Q4 2022 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2022.
Bristol Myers Squibb (BMY) Q3 2022 Earnings Call Transcript
BMY earnings call for the period ending September 30, 2022.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.